Goodrx is trading 6.7% up at $3.49 in after-hours trading following its second-quarter 2026 earnings release and raised full-year guidance. - Revenue of $200.4 million beat expectations, fueled by strong growth in Pharma Direct and subscription revenue. - Management raised 2026 revenue and adjusted EBITDA guidance, highlighting a strategic pivot toward higher-margin manufacturer partnerships. - Investors are rewarding the improved outlook and recurring revenue growth, while earnings per share were in line with estimates.